In previously treated KRAS G12C metastatic colorectal cancer, ifebemtinib plus garsorasib gave a confirmed response rate of 38·9% vs 16·7% with garsorasib alone in a 36-patient randomised phase 2 cohort; the difference was not significant (one-sided p=0·068).
RCTn = 51
Song et al. Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial